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Abstract
Background Osteoarthritis (OA) causes substantial pain
and reduced health-related quality of life (HRQL).
Although opioid analgesics are commonly used, the rela-
tive benefits of different opioids are poorly studied.
Transdermal buprenorphine (TDB) offers an alternative to
oral opioids for the treatment of moderate-to-severe
chronic pain. This observational study of people with OA
pain assessed satisfaction, HRQL and medication
adherence.
Methods Patients in the UK with self-reported knee and/or
hip OA who had been receiving one or more of TDB, co-
codamol (an oral paracetamol/codeine combination) and
tramadol for at least 1 month completed an online or
telephone questionnaire. Medication satisfaction scores,
HRQL scores (Short-Form 36 [SF-36]), medication
adherence (Morisky Medication Adherence Scale
[MMASTM]), adverse events and treatment discontinua-
tions were recorded. Linear and logistic regression models
were used to compare the treatment effect of TDB with co-
codamol or tramadol.
Results Overall, 966 patients met the inclusion criteria;
701 were taking only one of the target medications (TDB:
85; co-codamol: 373; tramadol: 243). The largest age group
was 50–59 years and 76.0 % of patients were female. The
TDB group was younger, with more male patients, there-
fore the statistical models were adjusted for age and sex.
Medication satisfaction scores were significantly higher in
the TDB group than the other two groups (TDB vs. co-
codamol: 3.56, 95 % confidence interval [CI] 1.90–6.68,
p\ 0.0001; TDB vs. tramadol: 3.22, 95 % CI 1.67–6.20,
p = 0.0005). Physical Component Summary scores for
HRQL and mean adherence were also higher in the TDB
group, while Mental Component Summary HRQL scores
were similar across the three groups.
Conclusions Patients with knee and/or hip OA pain treated
with TDB were more satisfied and more adherent with their
medication, and reported higher Physical Component
Summary HRQL scores than those treated with co-codamol
or tramadol, although demographic differences were
observed between groups.
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Key Points for Decision Makers
Low-dose transdermal buprenorphine (TDB) is an
effective alternative to oral opioids such as co-
codamol and tramadol for the treatment of moderate-
to-severe osteoarthritis (OA) pain.
This prospective, observational study showed that
patients with OA whose pain was treated with TDB
reported increased satisfaction with their medication,
better adherence, and improved Physical Component
Summary health-related quality of life scores
compared with patients treated with co-codamol or
tramadol.
Physicians should consider patient satisfaction and
quality of life when prescribing analgesics for
chronic pain.
1 Introduction
Osteoarthritis (OA) is a debilitating condition, charac-
terised by pain, joint inflammation and joint stiffness,
which causes a substantial degree of physical disability.
OA commonly affects the knee or the hip, and in England it
is estimated that 4.11 million people have knee OA (ap-
proximately 18 % of the population aged 45 years and
over) and 2.46 million have hip OA (approximately 11 %
of the population aged 45 years and over) [1]. Figures from
the US suggest approximately 13 % of women and 10 % of
men over 60 years of age have knee OA [2].
The pain caused by OA can have a substantial impact on
patients’ quality of life. In a 2012 online survey of OA
patients in the UK [3], 52 % of the 2001 respondents
reported that OA had a large impact on their life, 71 % had
persistent pain even after taking their prescribed pain
medication, and 12 % said their pain was often unbearable.
Opioid analgesics are commonly used to treat chronic
musculoskeletal pain, including OA pain. The National
Institute for Health and Care Excellence (NICE) OA
guidelines [4] recommend using opioids after other anal-
gesics such as paracetamol and oral non-steroidal anti-in-
flammatory drugs (NSAIDs) have failed or are
contraindicated. Similarly, the American College of
Rheumatology guidelines [5] recommend opioids for the
treatment of knee or hip OA pain in patients who have not
responded to initial non-opioid treatment. Tramadol is
considered separately to other opioids and is suggested as a
first-line treatment. In their guidelines for the treatment of
knee OA, The American Academy of Orthopaedic Sur-
geons [6] recommended the use of tramadol but were
unable to recommend other opioids or pain patches due to a
lack of published evidence that met their inclusion criteria.
At clinically prescribed doses, buprenorphine acts as a
full l-opioid agonist, and has a long duration of action
[7–9]. It has been shown to have no analgesic ceiling
effect, immunosuppressive activity or effect on gonadal
hormones [7, 8, 10, 11]. In addition, the dose of
buprenorphine does not need to be adjusted in elderly
patients [12–15] or those with renal impairment [16].
Buprenorphine is available in the UK as transdermal
patches (TDB), sublingual tablets, and as a solution for
injection. This study focused on low-dose 7-day TDB,
containing buprenorphine 5–20 mg with a nominal release
rate of 5–20 lg/h. These patches are indicated for moderate
chronic non-cancer pain, and have been shown to have
comparable efficacy to oral opioids for the treatment of OA
pain [17]. Two randomised controlled trials (RCTs) have
demonstrated that 7-day TDB is non-inferior to co-co-
damol (an oral paracetamol/codeine combination) and
tramadol for the treatment of OA pain [18, 19]. In addition,
a retrospective database study into the use of 7-day TDB in
primary care [20] found that significantly more patients
persisted with their treatment after 6 and 12 months com-
pared with codeine, dihydrocodeine and tramadol.
Tramadol has a dual mode of action as a l-opioid
agonist and as a weak serotonin and noradrenaline reuptake
inhibitor. It is available in the UK as immediate- or pro-
longed release oral tablets or capsules, as an oral solution,
and as a solution for injection or infusion. The maximum
recommended dose is 400 mg/day [21].
Co-codamol is a combination analgesic containing
codeine and paracetamol, which is commonly used in the
UK. Three different dose strengths are available: 8/500
(codeine 8 mg/paracetamol 500 mg), 15/500 and 30/500.
Codeine is a l-opioid agonist and co-codamol is available
in the UK as oral tablets or capsules. The maximum rec-
ommended daily dose is codeine 240 mg and paracetamol 4
g [21]. Codeine is a prodrug that is metabolised to mor-
phine via cytochrome P450 (CYP) 2D6 in the liver to exert
its analgesic effect.
Clinical trial data are essential for robust comparisons of
the efficacy of different treatments but rarely reflect the
way medicines are used in practice. Real-world evidence,
such as observational studies conducted without any
healthcare professional involvement, can provide useful
insights into how patients really use their medications, and
may help to inform prescribing decisions.
Despite opioid analgesics being recommended for suit-
able patients with OA pain, few studies have compared the
relative benefits of different opioids. Previous studies have
compared TDB with co-codamol and tramadol in an RCT
[18, 19] and general practice setting [20], but not from a
patient perspective.
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We conducted an observational study to assess TDB, co-
codamol and tramadol in patients with OA pain in a real-
world, non-interventional setting. Our primary objective
was to establish whether there were any differences
between the study medications in patient-reported out-
comes, including medication satisfaction, health-related
quality of life (HRQL) and adherence to treatment.
2 Method
2.1 Patients and Study Design
This was a UK-based observational study, conducted in
people with OA of the knee and/or hip, without any
intervention from a healthcare professional. Questionnaires
were completed online by the participants or conducted by
telephone interview. Recruitment was through social
media, general practitioner (GP) surgeries and pharmacies,
and advertisements in newspapers and on patient websites.
Please refer to the electronic supplementary material
(ESM) for further details of the questionnaire.
Participants were included in the study if they had a self-
reported diagnosis of knee and/or hip OA, and had been
prescribed one of the target analgesic medications (low-
dose 7-day TDB, co-codamol or tramadol) for their OA
pain for at least 1 month prior to study entry.
The study was conducted between September 2012 and
March 2013. Responses were measured at baseline (the
first questionnaire), and after 1, 2 and 3 months. Following
completion of the baseline questionnaire, patients were sent
reminders to complete the follow-up surveys. For each
follow-up, participants had up to 14 days to complete the
questionnaire after receiving a reminder, and each partici-
pant was contacted by email, SMS or telephone at least
three times to complete each follow-up survey.
The study was performed in accordance with the regula-
tions and guidelines governingmedical practice and ethics in
the UK. Study documents were reviewed and approved by
the appointed Research Ethics Committee (East of Scotland
Research Ethics Service [EoSRES]; ref: LR/12/ES/0093),
and all patients were provided with information about the
study and asked to consent either by telephone or online
before completing the baseline questionnaire.
2.2 Outcomes and Assessments
2.2.1 Patient Satisfaction
Satisfaction with current pain medication was assessed at
baseline using a 6-point Likert scale comprising ‘Very
satisfied’, ‘Satisfied’, ‘Neither satisfied nor dissatisfied’,
‘Dissatisfied’, ’Very dissatisfied’ and ‘No opinion’.
2.2.2 Health-Related Quality of Life (HRQL)
HRQL during the previous 4 weeks was assessed at base-
line and in each follow-up questionnaire using the Short-
Form 36, version 2 (SF-36v2; standard form) health survey,
which measures eight different areas of patients’ health:
physical functioning, role-physical, bodily pain, general
health, vitality, social functioning, role-emotional and
mental health. Scores were recorded for each of these
areas, and aggregate physical and mental scores (the
Physical Component Summary and Mental Component
Summary) were calculated. Scores range from 0–100, with
0 corresponding to low HRQL and 100 corresponding to
high HRQL.
2.2.3 Adherence
Adherence was measured at baseline and in each follow-up
questionnaire using the Morisky Medication Adherence
Scale (MMASTM), a set of eight questions designed to
identify medication use behaviour that can indicate non-
adherence. Scores from 0 to 8 are possible, with a score of
\6 indicating low adherence, 6–7 indicating medium
adherence, and 8 indicating high adherence.
2.2.4 Adverse Events (AEs)
AEs related to treatment were recorded at baseline. Rea-
sons for discontinuation were also recorded at baseline and
in each follow-up questionnaire, which included discon-
tinuations because of side effects.
2.3 Statistical Methods
Participants who met the inclusion criteria and had partially
or fully completed at least the baseline questionnaire were
included in the statistical analysis.
The full analysis population refers to all patients and
their actual treatment groups at the time of follow-up. Due
to the number of patients who changed treatment or
dropped out of the study, analysis for the follow-up ques-
tionnaires was carried out on two study populations:
• Intention-to-treat (ITT) population: analysis of subjects
as per their treatment groups at baseline, even if their
treatment group later changed.
• Per protocol (PP) population: analysis of subjects who
remained on the same treatment from baseline.
Follow-up data have been reported in this study using
the PP population.
Data were analysed descriptively; for categorical vari-
ables, the number and percentage falling into each category
were reported. Percentages were calculated from total
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numbers excluding any missing observations. For contin-
uous variables, the mean, standard deviation (SD), median,
interquartile range (IQR) and range were reported.
Estimates for the treatment effect of single target med-
ications (co-codamol and tramadol only) were obtained for
continuous and binary outcomes (medication satisfaction,
HRQL and treatment adherence) using linear and logistic
regression models, respectively, compared with TDB. Each
model included the treatment variable, with comparisons
focusing on the treatment effect of TDB compared with the
other two treatments. p-Values were provided for the dif-
ferences across all three treatment groups and the com-
parisons between TDB and co-codamol, and TDB and
tramadol. The estimates (or odds ratios where relevant) and
a 95 % confidence interval for each treatment effect were
also provided for the comparisons of TDB with co-codamol
and with tramadol to show the likelihood of the outcome
occurring in patients treated with TDB compared with
patients treated with the other medication. Initial models
were unadjusted, containing a covariate for treatment only.
As subjects in the TDB group were more likely to be
younger and/or male than those in the other groups, age-
and sex-adjusted models were also investigated to remove
potential bias in the results.
3 Results
3.1 Patient Characteristics
A total of 1011 patients completed the questionnaire, with
966 meeting the inclusion criteria (Fig. 1). Most of the
patients (76.0 %) were female, and 91.3 % of the study
population had been diagnosed with OA for 1 year or
Subjects completing 
baseline questionnaire
n = 1011
Subjects with knee and/or 
hip affected by OA
n = 986
Subjects in analysis 
population
n = 966
Subjects taking one target 
medication*
n = 701
Co-codamol
n = 373
TDB
n = 85
Tramadol
n = 243
Excluded subjects (n = 20)
• Not currently prescribed a target 
medication* for OA pain
(n = 3)
• Length of time on current target 
medication not known
(n = 3)
• Length of time on current target 
medication less than 1 month 
(n = 14)
Baseline
n = 203n = 35 n = 145
Follow-up 
Month 1
n = 149n = 17 n = 116
Follow-up 
Month 2
n = 130n = 11 n = 104
Follow-up 
Month 3
Fig. 1 Patient selection
process. Asterisk target
medications: 7-day TDB, co-
codamol or tramadol. These
figures are taken from the full
analysis population. The follow-
up numbers include participants
taking one target medication at
the time of each follow-up
questionnaire, although
participants may have moved
from another medication group
or may not have completed all
follow-up questionnaires. OA
osteoarthritis, TDB transdermal
buprenorphine
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more. Some of the patients were taking more than one of
the target medications; therefore, to enable more accurate
comparisons between the target medications, subjects tak-
ing a single target medication were analysed separately,
with patients categorised into the TDB-only, co-codamol-
only and tramadol-only groups.
3.1.1 Age and Sex Distribution
The study population included a range of ages, with the
largest proportion aged between 50 and 59 years (Table 1),
which was similar in all groups except the TDB group, in
which most patients were under 40 years of age. Similarly,
the sex distribution of the TDB group was different to the
other groups. The total analysis population was 76.0 %
female, with similar proportions in the co-codamol
(75.3 %) and tramadol (81.1 %) groups. In the TDB group,
45.8 % were female. Age- and sex-adjusted analysis was
performed to take into account differences in age and sex
distribution between the groups (see the ESM for analysis
results).
3.1.2 Comorbidities
Many of the patients had comorbidities alongside their OA,
with a mean of 1.4 concomitant conditions across all
groups. The most common condition was depression, seen
in just over 1 in 10 patients in the TDB-only group, com-
pared with approximately one-third in the co-codamol- and
tramadol-only groups. High blood pressure, high choles-
terol and type II diabetes were the next most commonly
reported conditions.
Table 1 Patient demographics All One target TDB Co-codamol Tramadol
Age, years
n (missing) 909 (57) 663 (38) 83 (2) 352 (21) 228 (15)
Under 40 126 (13.9) 107 (16.1) 41 (49.4) 49 (13.9) 17 (7.5)
40–49 179 (19.7) 127 (19.2) 15 (18.1) 66 (18.8) 46 (20.2)
50–59 367 (40.4) 259 (39.1) 13 (15.7) 131 (37.2) 115 (50.4)
60–69 186 (20.5) 133 (20.1) 6 (7.2) 85 (24.1) 42 (18.4)
70–79 40 (4.4) 29 (4.4) 5 (6.0) 17 (4.8) 7 (3.1)
80–89 9 (1.0) 6 (0.9) 2 (2.4) 3 (0.9) 1 (0.4)
C90 2 (0.2) 2 (0.3) 1 (1.2) 1 (0.3) 0 (0.0)
Sex
n (missing) 909 (57) 663 (38) 83 (2) 352 (21) 228 (15)
Male 218 (24.0) 175 (26.4) 45 (54.2) 87 (24.7) 43 (18.9)
Female 691 (76.0) 488 (73.6) 38 (45.8) 265 (75.3) 185 (81.1)
Years diagnosed with OA
n (missing) 966 (0) 701 (0) 85 (0) 373 (0) 243 (0)
\1 84 (8.7) 61 (8.7) 5 (5.9) 40 (10.7) 16 (6.6)
1–4 278 (28.8) 226 (32.2) 46 (54.1) 115 (30.8) 65 (26.7)
5–9 235 (24.3) 164 (23.4) 15 (17.6) 93 (24.9) 56 (23.0)
10–14 164 (17.0) 109 (15.5) 5 (5.9) 56 (15.0) 48 (19.8)
C15 205 (21.2) 141 (20.1) 14 (16.5) 69 (18.5) 58 (23.9)
Concomitant conditions
n (missing) 966 (0) 701 (0) 85 (0) 373 (0) 243 (0)
Depression 330 (34.2) 214 (30.5) 10 (11.8) 120 (32.2) 84 (34.6)
High blood pressure 317 (32.8) 217 (31.0) 17 (20.0) 115 (30.8) 85 (35.0)
High cholesterol 223 (23.1) 153 (21.8) 12 (14.1) 85 (22.8) 56 (23.0)
Diabetes type II 115 (11.9) 87 (12.4) 15 (17.6) 39 (10.5) 33 (13.6)
Angina 42 (4.3) 28 (4.0) 3 (3.5) 15 (4.0) 10 (4.1)
Heart attack 42 (4.3) 19 (2.7) 0 (0.0) 10 (2.7) 9 (3.7)
Renal/kidney disease 28 (2.9) 16 (2.3) 4 (4.7) 8 (2.1) 4 (1.6)
Other condition 394 (40.8) 269 (38.4) 18 (21.2) 142 (38.1) 109 (44.9)
Data are expressed as n (%) unless otherwise stated
TDB transdermal buprenorphine, OA osteoarthritis
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3.1.3 Target Medication Dose
In all groups, most patients had been taking their target
medication for 6 months or more (89.4 % in the TDB
group, 89.3 % in the co-codamol group and 91.8 % in the
tramadol group).
The median strength of TDB used was 15 lg/h over 7
days. This strength was used by 32.9 % of patients in the
TDB group. The lowest TDB strength was 5 lg/h, taken by
14.1 % of patients, and the highest strength was 30 lg/h
(8.2 % of patients).
In the co-codamol group, the median dose was 180/3000
mg/day (six 30/500 mg tablets, taken by 55.8 % of
patients). This was also the highest dose taken. The lowest
dose was 48/3000 mg/day (six 8/500 mg tablets, taken by
23.6 % of patients).
The median dose in the tramadol group was 300 mg/day
(taken by 58.4 % of patients), the lowest dose was 200
mg/day (6.6 % of patients), and the highest dose was 400
mg/day (35 % of patients).
3.1.4 Concomitant Medications
Many of the patients were taking concomitant non-target
pain medications, either prescribed, purchased over-the-
counter (OTC), or both prescribed and OTC. The use of
these other pain medications was broadly similar across the
three target medication groups (Table 2).
Nearly 30 % of patients taking one target medication
also took prescribed paracetamol. Nearly one-fifth took
OTC paracetamol, and 8.4 % took both prescribed and
OTC paracetamol. Although co-codamol contains parac-
etamol, 21.4 % of patients in the co-codamol group were
prescribed additional paracetamol, and 17.7 % bought
paracetamol OTC. Nearly 1 in 12 patients taking co-co-
damol were taking prescribed and OTC paracetamol in
addition to their co-codamol.
The total number of oral medications taken (for pain and
other conditions), in addition to the target medication, are
shown in Table A of the ESM. The proportions of patients
were fairly similar across the groups, except the ‘10 or
more’ oral medications category, which accounted for a
considerably higher percentage of the tramadol group than
the TDB or co-codamol groups.
3.2 Patient Satisfaction
At baseline, nearly 80 % of patients in the TDB group
reported being either ‘very satisfied’ or ‘satisfied’ with
their medication, compared with fewer than 40 % of
patients in both the co-codamol and tramadol groups
(Fig. 2); this difference was statistically significant. When
adjusted for age and sex, the estimated treatment effect for
TDB vs. co-codamol was 3.56 (95 % CI 1.90–6.68;
p\ 0.0001). For TDB vs. tramadol, the estimated treat-
ment effect was 3.22 (95 % CI 1.67–6.20; p = 0.0005).
3.3 HRQL
The SF-36 Physical Component Summary and Mental
Component Summary scores for each group at baseline are
shown in Table 3. The mean Physical Component
Table 2 Other pain medications taken by patients
All [N = 966] One target [N = 701] TDB [N = 85] Co-codamol [N = 373] Tramadol [N = 243]
Other medications (prescribed)
Paracetamol 279 (28.9) 205 (29.2) 19 (22.4) 80 (21.4) 106 (43.6)
Codeine-containing 124 (12.8) 93 (13.3) 24 (28.2) 47 (12.6) 22 (9.1)
Oral NSAID 401 (41.5) 296 (42.2) 46 (54.1) 160 (42.9) 90 (37.0)
Any topical 350 (36.2) 241 (34.4) 39 (45.9) 121 (32.4) 81 (33.3)
Other medications (OTC)
Paracetamol 160 (16.6) 131 (18.7) 18 (21.2) 66 (17.7) 47 (19.3)
Codeine-containing 96 (9.9) 77 (11.0) 22 (25.9) 41 (11.0) 14 (5.8)
Oral NSAID 217 (22.5) 170 (24.3) 39 (45.9) 97 (26.0) 34 (14.0)
Any topical 351 (36.3) 264 (37.7) 37 (43.5) 149 (39.9) 78 (32.1)
Other medications (prescribed and OTC)
Paracetamol 74 (7.7) 59 (8.4) 6 (7.1) 29 (7.8) 24 (9.9)
Codeine-containing 22 (2.3) 16 (2.3) 4 (4.7) 7 (1.9) 5 (2.1)
Oral NSAID 142 (14.7) 117 (16.7) 32 (37.6) 62 (16.6) 23 (9.5)
Any topical 127 (13.1) 86 (12.3) 20 (23.5) 41 (11.0) 25 (10.3)
Data are expressed as n (%)
TDB transdermal buprenorphine, NSAID non-steroidal anti-inflammatory drug, OTC over-the-counter
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Summary score was higher in the TDB group (38.39) than
in both the co-codamol (30.99) and tramadol (27.83)
groups. In the age- and sex-adjusted analysis, this differ-
ence was statistically significant for the TDB group when
compared with the tramadol group (p\ 0.0001), but not
when compared with the co-codamol group (p = 0.0910).
No significant differences in the Mental Component
Summary scores were observed between the groups. The
scores from the follow-up questionnaires from months 1, 2
and 3 are shown in Table 4. The Physical Component
Summary results were broadly similar to baseline after
1 month, but after 2 and 3 months the treatment differences
were smaller. For the Mental Component Summary scores,
all of the follow-up results showed that mean scores were
numerically higher in patients taking co-codamol and tra-
madol than those taking TDB, but that these differences
were not significant.
3.4 Adherence
The mean MMAS score in the TDB group at baseline was
6.01, which corresponds to ‘medium adherence’. Mean
results for the co-codamol and tramadol groups were 5.24
and 5.73, respectively, putting both groups in the ‘low
adherence’ category. The mean MMAS score in the TDB
group was significantly higher than the mean scores for
both the co-codamol and tramadol groups. The adjusted
analysis showed that the estimated treatment effect for
TDB vs. co-codamol was 1.07 (95 % CI 0.57–1.56;
p\ 0.0001), and 0.54 (95 % CI 0.02–1.07; p = 0.0435)
for TDB vs. tramadol.
Looking at the trends in individual scores at baseline, there
were more patients in the TDB group with high and medium
adherence, and fewer patients with low adherence, compared
with the co-codamol and tramadol groups (Fig. 3). Results for
each question are shown in Table B of the ESM.
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Fig. 2 Patient satisfaction with their current pain medication. Mea-
sured at baseline in patients taking one target medication (TDB,
n = 85; co-codamol, n = 373; tramadol, n = 243). ‘Other’ includes
‘Neither satisfied nor dissatisfied’, ‘Dissatisfied’, ‘Very dissatisfied’
and ‘No opinion’. TDB transdermal buprenorphine
Table 3 SF-36 Physical Component and Mental Component Scores at baseline
Analysis population One target TDB Co-codamol Tramadol
SF-36 Physical Component Summary
n (missing) 965 (1) 701 (0) 85 (0) 373 (0) 243 (0)
Mean (SD) 29.40 (9.85) 30.79 (10.08) 38.39 (11.52) 30.99 (9.73) 27.83 (8.54)
Median (IQR) 27.37 (22.35–36.25) 28.65 (23.30–38.34) 44.68 (27.13–47.34) 28.90 (23.91–37.77) 26.83 (22.24–32.42)
Min, max 5.42, 55.37 5.48, 55.37 14.41, 51.33 11.20, 55.37 5.48, 51.82
Adjusted analysis
p-Value for difference across all three treatment groups p\ 0.0001
Buprenorphine vs. co-codamol treatment difference 1.75 (95 % CI -0.28 to 3.78) p = 0.0910
Buprenorphine vs. tramadol treatment difference 4.29 (95 % CI 2.12–6.46) p\ 0.0001
SF-36 Mental Component Summary
n (missing) 965 (1) 701 (0) 85 (0) 373 (0) 243 (0)
Mean (SD) 33.94 (12.78) 35.63 (12.51) 36.99 (8.73) 35.19 (12.67) 35.84 (13.36)
Median (IQR) 34.35 (25.77–42.24) 35.03 (27.04–42.35) 36.18 (33.38–38.67) 34.36 (26.07–42.39) 35.41 (26.42–44.84)
Min, max 0.88, 72.58 8.42, 67.78 12.83, 59.68 8.42, 67.78 8.95, 66.41
Adjusted analysis
p-Value for difference across all three treatment groups p = 0.4204
Buprenorphine vs. co-codamol treatment difference 1.68 (95 % CI -1.46 to 4.82) p = 0.2945
Buprenorphine vs. tramadol treatment difference 0.62 (95 % CI -2.75 to 3.98) p = 0.7193
SF-36 Short-Form 36, TDB transdermal buprenorphine, SD standard deviation, IQR interquartile range, min minimum, max maximum, CI
confidence interval
Satisfaction, Adherence and Health-Related Quality of Life with Transdermal Buprenorphine 365
After 1 month, adherence results were broadly similar to
those recorded at baseline, with mean MMAS total scores
of 6.33 for TDB, 5.45 for co-codamol, and 5.61 for tra-
madol. More patients in the TDB group were classed as
having high and medium adherence, and fewer patients had
low adherence, than in the co-codamol and tramadol
groups. However, at months 2 and 3, there were very few
differences between the groups.
Table 4 SF-36 Physical Component Score and Mental Component Score recorded at 1, 2 and 3 months
TDB Co-
codamol
Tramadol Adjusted analysis
SF-36 Physical Component Summary
Month 1
n 29 190 136 p-Value for difference across all three treatment
groups
0.035
Buprenorphine vs. co-codamol treatment
difference
0.82 (95 % CI -2.44, 4.09),
p = 0.620
Mean (SD) 32.91
(10.99)
30.00
(8.88)
27.15 (8.07) Buprenorphine vs. tramadol treatment difference 3.03 (95 % CI -0.36, 6.43),
p = 0.080
Month 2
n 14 138 102 p-Value for difference across all three treatment
groups
0.151
Buprenorphine vs. co-codamol treatment
difference
-0.64 (95 % CI -5.06,
3.77), p = 0.775
Mean (SD) 28.34
(5.73)
29.47
(8.47)
27.22 (8.10) Buprenorphine vs. tramadol treatment difference 1.43 (95 % CI -3.09, 5.95),
p = 0.534
Month 3
n 9 114 87 p-Value for difference across all three treatment
groups
0.267
Buprenorphine vs. co-codamol treatment
difference
-0.25 (95 % CI -5.67,
5.17), p = 0.928
Mean (SD) 28.34
(4.37)
29.90
(9.26)
27.62 (7.35) Buprenorphine vs. tramadol treatment difference 1.63 (95 % CI -3.87, 7.14),
p = 0.559
SF-36 Mental Component Summary
Month 1
n 29 190 136 p-Value for difference across all three treatment
groups
0.341
Buprenorphine vs. co-codamol treatment
difference
-3.39 (95 % CI -8.42,
1.63), p = 0.185
Mean (SD) 34.34
(10.39)
37.28
(12.83)
34.53
(13.71)
Buprenorphine vs. tramadol treatment difference -3.88 (95 % CI -9.10,
1.35), p = 0.145
Month 2
n 14 138 102 p-Value for difference across all three treatment
groups
0.139
Buprenorphine vs. co-codamol treatment
difference
-3.94 (95 % CI -11.2,
3.32), p = 0.286
Mean (SD) 33.92
(9.20)
36.98
(13.69)
38.40
(12.86)
Buprenorphine vs. tramadol treatment difference -6.49 (95 % CI -13.9,
0.95), p = 0.087
Month 3
n 9 114 87 p-Value for difference across all three treatment
groups
0.247
Buprenorphine vs. co-codamol treatment
difference
-2.77 (95 % CI -11.4,
5.90), p = 0.530
Mean (SD) 33.19
(10.75)
35.94
(12.49)
36.93
(13.45)
Buprenorphine vs. tramadol treatment difference -5.42 (95 % CI -14.2,
3.39), p = 0.227
SF36 Short-Form 36, TDB transdermal buprenorphine, SD standard deviation
366 P. G. Conaghan et al.
3.5 Reasons for Discontinuation
Reasons for discontinuation at months 1, 2 and 3 for the
full analysis population are shown in Table C of the ESM.
Although the numbers of patients who recorded reasons for
discontinuation were small, discontinuations due to side
effects were more common in the co-codamol and tramadol
groups than in the TDB group.
3.6 Adverse Events
AEs were reported by 30.6 % of patients in the TDB group,
compared with 53.4 % in the co-codamol group and
55.1 % in the tramadol group (Table D of the ESM). The
incidence of constipation was much higher in the co-co-
damol group (23.9 %) than in the TDB group (9.4 %) or
tramadol group (10.3 %); dizziness occurred in more
patients in the tramadol group (10.7 %) than the TDB
group (5.9 %) or co-codamol group (6.7 %); somnolence
was reported in only 1.2 % of patients in the TDB group
compared with 11.3 % in the co-codamol group and
14.8 % in the tramadol group; and psychiatric disorders
were reported in more patients in the tramadol group
(11.1 %) than the TDB group (1.2 %) or the co-codamol
group (4.6 %).
4 Discussion
We believe this is the first study comparing patient-re-
ported outcomes for medication satisfaction, HRQL and
treatment adherence between different opioid analgesics in
the treatment of OA pain. Previous studies have demon-
strated comparable analgesia between TDB and co-co-
damol and tramadol [18, 19]. The intention was to
highlight the other potential benefits of using a patch
besides pain relief that may be important to patients, such
as satisfaction with their medication or improvements in
HRQL. TDB has the convenience of once-weekly admin-
istration and reduces the overall pill burden [18], which
may be particularly important for patients with concomi-
tant conditions who are taking multiple medications.
Patients in the current study with additional medical con-
ditions may have already been taking a number of non-
analgesic medicines every day. The additional conditions
most commonly reported in this study were depression,
high blood pressure, high cholesterol and type II diabetes,
which are all likely to require long-term medication use.
Analgesic patches provide continuous pain relief without
the risk of peaks and troughs of dosing that might be seen
when taking regular oral analgesics. The patches may be
useful for patients who are unable to take oral medications
or have difficulty swallowing.
This study indicates that patients prescribed TDB for
self-reported OA pain are more satisfied with their medi-
cation compared with patients taking co-codamol or tra-
madol. It would seem logical that increased patient
satisfaction with pain medication might improve treatment
adherence, and consequently patient outcomes, but there
have been few studies looking at this for pain. Hirsh et al.
[22] suggested a link between patient satisfaction and
compliance with treatment in patients with chronic pain.
However, a recent study showed that adherence and
treatment satisfaction were not linked to quality-of-life
outcomes in patients with chronic pain [23]. In our study,
patients in the TDB group reported both greater treatment
satisfaction and higher Physical Component Summary SF-
36 scores compared with the co-codamol and tramadol
groups. At baseline, the difference in Physical Component
Summary SF-36 scores in the TDB group was statistically
significant compared with tramadol, and scores were
numerically higher compared with co-codamol.
Quality of life is an important consideration in the
treatment of chronic pain patients. All aspects of quality of
life are compromised when pain is inadequately treated,
and effective pain relief has been shown to improve HRQL
[24]. When patients with chronic pain were asked to rank
aspects of quality of life impacted by their condition, they
highlighted enjoyment of life, fatigue, emotional wellbeing
and physical activities as the most important areas they
would consider when evaluating the success of their pain
treatment [25]. Our study indicates that SF-36 Physical
Component Summary HRQL scores are higher for patients
prescribed TDB compared with co-codamol or tramadol.
After adjusting for age and sex, the treatment difference in
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Fig. 3 Patient adherence with their pain medication. Percentages of
patients in each target medication group with high, medium and low
adherence, according to the Morisky Medication Adherence Scale.
N = 701 patients taking one target medication: TDB, n = 85; co-
codamol, n = 373; tramadol, n = 243. TDB transdermal
buprenorphine
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SF-36 Physical Component Summary score between the
TDB and co-codamol groups was 1.75, which was not
statistically significant (p .0910); however, the difference
between the TDB and tramadol groups was 4.29. As well
as being statistically significant (p\ 0.0001), this is also
likely to be clinically relevant. For patients with OA of the
lower extremities, the minimal clinically important differ-
ence (MCID) for SF-36 scores has been reported as ranging
from 2.0 to 7.8 depending on the subscale used; for the
Physical Component Summary, 2.0 was suggested as the
MCID to show improvement [26]. In the current study,
after 1 month the SF-36 Physical Component Summary
scores were broadly similar to baseline, with smaller
treatment differences after 2 and 3 months. However, the
number of patients in the TDB group completing ques-
tionnaires at months 2 and 3 was too low for any conclu-
sions to be drawn from these data. In all three of the
follow-up questionnaires, SF-36 Mental Component Sum-
mary scores were better for patients taking co-codamol or
tramadol than for patients taking TDB; however, these
differences were not significant. Over one-third of patients
in the study reported depression as a comorbidity. This was
not unexpected as depression is very common in people
with chronic pain, and it is therefore important for pain to
be treated using a biopsychosocial model [27]. It is possible
that the high level of depression reported in the study
population affected the SF-36 Mental Component Sum-
mary scores and may have contributed to the lack of dif-
ferences seen in these scores between the groups.
Adherence is difficult to measure in clinical studies
because of increased monitoring, and possibly increased
awareness, by patients that their adherence is being mea-
sured. Real-world studies may be more useful for mea-
suring adherence but often (as in this study) rely on patients
accurately recalling and reporting their medication use
behaviour. The results of this study suggest that patients in
the TDB group show medium adherence to their medicine
compared with low adherence in the co-codamol and tra-
madol groups. To qualify for high adherence, a patient
would need a perfect score on the MMAS questionnaire.
For example, this means they must never forget a dose or
forget to take their medicine with them when travelling.
When considering patch medications, some of the ques-
tions may be misleading; for example, asking if there were
any days in the last week when the medication was not
taken, or if the medication was taken yesterday. Patients
could misinterpret these questions as asking whether they
had applied a patch on the days in question, when in reality
they would be ‘taking’ their medication on any of the 7
days after patch application. Many patients with OA are
likely to be prescribed a number of different medications,
both for pain and other comorbid conditions; however,
increasing numbers of concomitant medications have been
linked with a decrease in medication adherence [28]. This
is an increasing problem, particularly in older people. A
recent review of Scottish medical records found that in
2010, 17.2 % of people over 65 years of age were pre-
scribed 10 medications in an 84-day period [29]. In our
study, most of the patients (just over one-third) were taking
between three and five additional oral medications, with
8.7 % of the overall study population and 21.0 % of
patients in the tramadol group taking over 10 additional
oral medications. Once-weekly transdermal patches are
likely to be easier for patients to remember to use than oral
medications, which could help to explain the improved
adherence seen with TDB compared with co-codamol and
tramadol in this study. Importantly, patients in the TDB
group were younger than those in the co-codamol and
tramadol groups, which may also have contributed to the
improved compliance. The convenience of a medicine is
likely to be important for people who are working, and oral
medication may be less convenient than a transdermal
patch. For example, a patient who has been prescribed
tablets may forget to take their medicine to work with
them, it could be inconvenient to stop work to administer
their dose, or the patient might forget to take their tablets at
the right time while working. In this study, the patient
population in the TDB group was predominantly of working
age, and the potential convenience benefits of a patch for-
mulation could account for the increased adherence seen in
the TDB group. Although the follow-up results were similar
after 1 month, there were few differences between the
groups after 2 and 3 months. Again, the number of TDB
patients completing questionnaires at months 2 and 3 was
too low for any conclusions to be drawn.
People with OA pain often take a combination of dif-
ferent analgesic medications [4]. In the current study,
patients were divided into groups depending on the target
medication they were taking (TDB, co-codamol or tra-
madol), but 265 patients were taking two or more of the
target medications and were removed from the medication-
specific analyses. Many patients were also taking con-
comitant non-target pain medications. However, use of
these other pain medications was broadly similar across the
three target medication groups, allowing comparisons to be
made between the groups. A substantial proportion of
patients were taking prescribed and/or OTC paracetamol in
addition to the target medication, even for patients already
receiving paracetamol from co-codamol. It is important to
consider the risk of toxicity in these patients taking high
doses of paracetamol. A recent review has suggested that
paracetamol may be linked to cardiovascular, gastroin-
testinal and renal side effects, even at standard therapeutic
doses [30]. In addition, high use of paracetamol may
indicate that the intensity of patients’ pain and recom-
mended treatment guidelines are not being taken into
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account in the management of OA pain [31]. Higher pro-
portions of patients in the TDB group were using con-
comitant analgesics (including prescribed, OTC, and
prescribed/OTC) compared with the co-codamol and tra-
madol groups. It is possible this could have contributed to
the improved satisfaction, SF-36 Physical Component
Summary HRQL, and adherence scores in the TDB group.
It is likely that many patients in this study were self-ad-
ministering their OTC pain medications without notifying
their GP. Physicians should consider this and ask about
OTC medication use at each consultation to ensure pre-
scribed analgesia is suitable for the patient’s level of pain,
and to reduce the need for the patient to make unnecessary
pharmacy visits. Regular pain assessments would also be
beneficial, ensuring pain is being treated appropriately in
each patient.
AEs reported in this study were typical of those seen
with opioid medications. The proportion of patients expe-
riencing AEs was smaller in the TDB group than in the co-
codamol or tramadol groups. Constipation was more
common in the co-codamol group than the TDB and tra-
madol groups, and is a well-known side effect of codeine,
which has been described as ‘‘too constipating for long-
term use’’ [21]. Constipation can have a large impact on
patients’ quality of life. In a survey of patients taking
opioids and laxatives, it was shown that constipation was
the ‘most bothersome’ gastrointestinal side effect of opi-
oids [32] and does not decrease over time as with other
opioid side effects. Nervous system disorders and psychi-
atric disorders occurred more often in the tramadol group
than the TDB or co-codamol groups. This included dizzi-
ness, which can be a particular problem in the elderly, and
is present in some form in 30 % of people over 65 years of
age, and 50 % of people aged 85 years and over. Almost
60 % of older primary care patients with dizziness expe-
rience a moderate or severe impact on their daily life as a
result [33]. Dizziness has been linked to anxiety and
avoidance behaviour, such as avoiding crowds and being
away from home, and can also cause occupational prob-
lems in people of working age [34].
The high dropout rate over the study period was mostly
due to patients not completing the follow-up question-
naires, rather than discontinuation of treatment. This
highlights the difficulties in carrying out this type of
research in patients without healthcare professional input.
Because of the drop in patient numbers, the main statistics
in this study have been taken from the baseline population.
However, the results are still a valid measure of patients’
opinions and treatment outcomes as most of the patients
had been stabilised on their medication for 6 months or
more, and were not new patients. We did not expect so
many long-term patients when we designed the study, and
thought that the follow-up questionnaires would show
differences, for example as patients changed treatments due
to side effects or lack of efficacy. In reality, even if patient
numbers had been higher at follow-up, we would have been
unlikely to see much difference from baseline in a popu-
lation largely well-established on their target medication.
As this study had no healthcare professional involve-
ment, some of the information collected may not be as
accurate as in a controlled clinical trial, where source data
are verified. For example, the self-reported diagnosis of OA
was not medically confirmed. However, self-reported OA
has recently been shown to have high specificity when
compared with a radiographic diagnosis of OA [35].
Patients’ recall of information such as current and recent
medications and concomitant conditions may be unreliable.
In addition, as this was a non-randomised, non-blinded
study, factors that may have influenced the type of anal-
gesic each patient was prescribed may have had an effect
on their responses to questions. The treatment groups in the
study were unequal, with the co-codamol group over four
times larger than the TDB group, although this may reflect
the proportion of OA patients taking each medication in the
wider population. The TDB group was noticeably younger
than the other groups analysed in this study, and younger
than the average ages in most OA studies. This could be
due to the use of social media and online advertising for
patient recruitment, which may have led to selection bias,
favouring younger and more IT-literate patients; however,
this would have affected all groups equally. It is also
possible that healthcare professionals prefer to prescribe
TDB for younger patients of working age because it is less
intrusive on their daily schedule as it does not require
regular administration throughout the day. The TDB group
was quite different to the other groups in terms of gender
balance, with a much higher proportion of male subjects. It
is not clear why there was this gender recruitment differ-
ence, as, for example, IT literacy would not be expected to
be different by gender. It is possible that GPs were more
cautious about using oral opioids in younger males [36],
although we have no supporting data. Although an age- and
sex-adjusted analysis was performed, the differences in
patient numbers and demographics between the groups
should be taken into account when interpreting the results
of this study. In addition, due to the drop in patient num-
bers after the baseline questionnaire, it is difficult to
interpret the significance of any trends seen in the follow-
up results.
5 Conclusions
Although there were between-group differences in patient
demographics, this observational study showed that
patients prescribed TDB for their hip and/or knee OA pain
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had higher scores for medication satisfaction, SF-36
Physical Component Summary HRQL measures, and
medication adherence than those taking co-codamol or
tramadol, two commonly-used oral opioids.
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